Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(9):1369–1374. doi: 10.1038/bjc.1996.551

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

A M Burger 1, J A Double 1, J Konopa 1, M C Bibby 1
PMCID: PMC2074789  PMID: 8912531

Abstract

Novel imidazoacridinone derivatives, C1310 and C1311, have been evaluated for their potential to inhibit tumour cell growth in vitro and in vivo. A cell line panel, including seven human and murine colon carcinoma cell lines and three in vivo models, was used. The compounds were found to be potent inhibitors of tumour cell growth with IC50 values ranging between 10 nM and 2 microM in human colon cancer cell lines. Statistically significant tumour growth delay (P < 0.01) was observed after a single intraperitoneal (i.p.) dose of C1311 (100 mg kg-1 body weight) in MAC15A, MAC29 murine and HT29 human adenocarcinomas of the colon. Rapid accumulation of fluorescence of both C1310 and C1311 was seen in the nuclei of HT29 human colon tumour cells in culture. C1311 was also found to bind into calf thymus DNA as shown by spectrophotometric titration and thermal denaturation and to cause early inhibition of thymidine incorporation in HT29 cells in vitro. The results of this study suggest that C1311 should be considered as a candidate for clinical development.

Full text

PDF
1369

Images in this article

1372Figure 3
on p.1372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988 Feb 1;48(3):589–601. [PubMed] [Google Scholar]
  2. Blake A., Peacocke A. R. The interaction of aminocridines with nucleic acids. Biopolymers. 1968;6(9):1225–1253. doi: 10.1002/bip.1968.360060902. [DOI] [PubMed] [Google Scholar]
  3. Cheson B. D. The purine analogs--a therapeutic beauty contest. J Clin Oncol. 1992 Mar;10(3):352–355. doi: 10.1200/JCO.1992.10.3.352. [DOI] [PubMed] [Google Scholar]
  4. Cholody W. M., Martelli S., Konopa J. 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem. 1990 Oct;33(10):2852–2856. doi: 10.1021/jm00172a028. [DOI] [PubMed] [Google Scholar]
  5. Cholody W. M., Martelli S., Paradziej-Lukowicz J., Konopa J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem. 1990 Jan;33(1):49–52. doi: 10.1021/jm00163a009. [DOI] [PubMed] [Google Scholar]
  6. Collard J., Matthew A. M., Double J. A., Bibby M. C. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer. 1995 Jun;71(6):1199–1203. doi: 10.1038/bjc.1995.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Denny W. A. DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anticancer Drug Des. 1989 Dec;4(4):241–263. [PubMed] [Google Scholar]
  8. Diaz-Rubio E., Aranda E., Martin M., Gonzalez-Mancha R., Gonzalez-Larriba J., Barneto I. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer. 1990;26(6):727–729. doi: 10.1016/0277-5379(90)90128-g. [DOI] [PubMed] [Google Scholar]
  9. Double J. A., Ball C. R., Cowen P. N. Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst. 1975 Jan;54(1):271–275. doi: 10.1093/jnci/54.1.271. [DOI] [PubMed] [Google Scholar]
  10. Double J. C., Brown J. R. The interaction of aminoalkylaminoanthraquinones with deoxyribonucleic acid. J Pharm Pharmacol. 1975 Jul;27(7):502–507. doi: 10.1111/j.2042-7158.1975.tb09492.x. [DOI] [PubMed] [Google Scholar]
  11. Drlica K., Franco R. J. Inhibitors of DNA topoisomerases. Biochemistry. 1988 Apr 5;27(7):2253–2259. doi: 10.1021/bi00407a001. [DOI] [PubMed] [Google Scholar]
  12. FARBER S., D'ANGIO G., EVANS A., MITUS A. Clinical studies on actinomycin D with special reference to Wilms' tumor in children. Ann N Y Acad Sci. 1960 Oct 5;89:421–425. doi: 10.1111/j.1749-6632.1960.tb20165.x. [DOI] [PubMed] [Google Scholar]
  13. Furlong N. B., Sato J., Brown T., Chavez F., Hurlbert R. B. Induction of limited DNA damage by the antitumor agent Cain's acridine. Cancer Res. 1978 May;38(5):1329–1335. [PubMed] [Google Scholar]
  14. Hernandez L., Cholody W. M., Hudson E. A., Resau J. H., Pauly G., Michejda C. J. Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Res. 1995 Jun 1;55(11):2338–2345. [PubMed] [Google Scholar]
  15. Hill S. R., Pollard L. A., Bibby M. C. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. Anticancer Res. 1992 Nov-Dec;12(6B):2169–2175. [PubMed] [Google Scholar]
  16. Islam S. A., Neidle S., Gandecha B. M., Partridge M., Patterson L. H., Brown J. R. Comparative computer graphics and solution studies of the DNA interaction of substituted anthraquinones based on doxorubicin and mitoxantrone. J Med Chem. 1985 Jul;28(7):857–864. doi: 10.1021/jm00145a003. [DOI] [PubMed] [Google Scholar]
  17. Kuśnierczyk H., Chołody W. M., Paradziej-Lukowicz J., Radzikowski C., Konopa J. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz) 1994;42(5-6):415–423. [PubMed] [Google Scholar]
  18. Mazerska Z., Lukowicz J., Konopa J. Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors. Arzneimittelforschung. 1990 Apr;40(4):472–477. [PubMed] [Google Scholar]
  19. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991 Jun 5;83(11):757–766. doi: 10.1093/jnci/83.11.757. [DOI] [PubMed] [Google Scholar]
  20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  21. Neidle S., Pearl L. H., Skelly J. V. DNA structure and perturbation by drug binding. Biochem J. 1987 Apr 1;243(1):1–13. doi: 10.1042/bj2430001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Phillips R. M., Bibby M. C., Double J. A. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst. 1990 Sep 19;82(18):1457–1468. doi: 10.1093/jnci/82.18.1457. [DOI] [PubMed] [Google Scholar]
  23. Plumbridge T. W., Aarons L. J., Brown J. R. Problems associated with analysis and interpretation of small molecule/macromolecule binding data. J Pharm Pharmacol. 1978 Feb;30(2):69–74. doi: 10.1111/j.2042-7158.1978.tb13164.x. [DOI] [PubMed] [Google Scholar]
  24. Plumbridge T. W., Brown J. R. The interaction of adriamycin and adriamycin analogues with nucleic acids in the B and A conformations. Biochim Biophys Acta. 1979 Jun 20;563(1):181–192. doi: 10.1016/0005-2787(79)90019-4. [DOI] [PubMed] [Google Scholar]
  25. Ramonas L. M., Erickson L. C., Klesse W., Kohn K. W., Zaharko D. S. Differential cytotoxicity and DNA cross-linking produced by polymeric and monomeric activated analogues of cyclophosphamide in mouse L1210 leukemia cells. Mol Pharmacol. 1981 Mar;19(2):331–336. [PubMed] [Google Scholar]
  26. Roberts J. J., Pascoe J. M. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature. 1972 Feb 4;235(5336):282–284. doi: 10.1038/235282a0. [DOI] [PubMed] [Google Scholar]
  27. Skladanowski A., Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol. 1993 Aug 3;46(3):375–382. doi: 10.1016/0006-2952(93)90512-u. [DOI] [PubMed] [Google Scholar]
  28. Skladanowski A., Plisov S. Y., Konopa J., Larsen A. K. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol. 1996 May;49(5):772–780. [PubMed] [Google Scholar]
  29. Weiss R. B., Sarosy G., Clagett-Carr K., Russo M., Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18(3):185–197. doi: 10.1007/BF00273384. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES